Skip to main content
Contact Us
Subscribe
E-Edition
53°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Argenx Se ADR
(NQ:
ARGX
)
605.92
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Argenx Se ADR
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Guess? Posts Upbeat Earnings, Joins Lufax, Nortech Systems And Other Big Stocks Moving Higher On Thursday
March 21, 2024
U.S. stocks were higher, with the Dow Jones index gaining around 250 points on Thursday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is European Pharma Giant Argenx Valued At Over $20B Trading Higher On Thursday?
March 21, 2024
Argenx shares rise on Chugai's gMG trial disappointment. FDA-approved Vyvgart for anti-acetylcholine receptor antibody-positive adult patients. Enspryng's Phase 3 study results disappoint. Vyvgart...
Via
Benzinga
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
March 21, 2024
Investors saw Chugai's experimental drug as a potential rival to Argenx's approved medicine, Vyvgart.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
March 21, 2024
Via
Benzinga
Earnings Scheduled For February 29, 2024
February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
Via
Benzinga
Why Is Argenx (ARGX) Stock Down 25% Today?
December 20, 2023
Following a late-stage clinical disappointment, Argenx has been forced back to the drawing board, thus cratering ARGX stock.
Via
InvestorPlace
Why Micron Therapies Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
March 21, 2024
Shares of Micron Technology, Inc. (NASDAQ: MU) rose sharply in today’s pre-market trading as the company reported upbeat results for its second quarter and issued
Via
Benzinga
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
March 07, 2024
From
argenx SE
Via
GlobeNewswire
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
February 29, 2024
From
argenx SE
Via
GlobeNewswire
argenx to Present at Upcoming Investor Conferences
February 26, 2024
From
argenx SE
Via
GlobeNewswire
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
February 22, 2024
From
argenx SE
Via
GlobeNewswire
3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition
February 21, 2024
Now could be the time to start looking into these biotech stocks as there are imminent approvals on their clinical trials.
Via
InvestorPlace
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
February 20, 2024
From
argenx SE
Via
GlobeNewswire
5 medical stocks growing earnings by triple digits
February 06, 2024
There is a little known way to pick stocks like the pros do, and today's exercise points you to five high-probability winners in a sector that's quickly turning
Via
MarketBeat
Topics
Economy
Exposures
Economy
New Hope For Patients With Chronic Autoimmune Conditions: Johnson & Johnson's Investigational Drug Meets Primary Goal In Two Studies
February 05, 2024
Johnson & Johnson's nipocalimab shows promise in Phase 3 VIVACITY for gMG & Phase 2 DAHLIAS for SjD. FDA-approved Vyvgart Hytrulo for gMG.
Via
Benzinga
Halozyme's Ambitious Five-Year Plan: Analysts Optimistic On Growth, Eyeing Market Expansion
January 18, 2024
Explore Halozyme Therapeutics' promising financial outlook up to 2028. Discover revenue forecasts, earnings projections, and market insights.
Via
Benzinga
argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis
January 18, 2024
From
argenx SE
Via
GlobeNewswire
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond
January 15, 2024
These five biotech companies could have a lot of room to run.
Via
The Motley Fool
argenx Highlights 2024 Strategic Priorities
January 08, 2024
From
argenx SE
Via
GlobeNewswire
argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
argenx SE
Via
GlobeNewswire
Stock Market Rally Is In Merry Mood Heading Into Christmas Weekend: Weekly Review
December 22, 2023
Despite a Wednesday tumble, the major indexes are right at 2023 highs.
Via
Investor's Business Daily
Argenx's Autoimmune Trial Stumble: Analysts Cut Price Targets, Warn of Risky Outcomes
December 21, 2023
Wednesday, Argenx SE (NASDAQ: ARGX) released topline results from the ADDRESS Phase 3 study evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with pemphigus...
Via
Benzinga
Immunovant Scores Much-Needed Win Following Argenx-Led Sell-off
December 21, 2023
Immunovant reversed its fortunes Thursday following an Argenx-tied selloff Wednesday.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
December 21, 2023
Via
Benzinga
Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Thursday
December 21, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Why Steelcase Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
December 20, 2023
Steelcase Inc. (NYSE: SCS) shares moved higher during Wednesday's session following quarterly results.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
December 20, 2023
Via
Benzinga
Why Is European Drugmaker Argenx Stock Sinking Today?
December 20, 2023
Argenx SE (NASDAQ: ARGX) shares plunged after the company released topline results from the ADDRESS Phase 3 study evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in...
Via
Benzinga
Why Aclarion Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket
December 20, 2023
Shares of Aclarion, Inc. (NASDAQ: ACON) shares rose sharply in pre-market trading after the company was granted U.S. patent #11844601 for "MR SPECTROSCOPY SYSTEM FOR DIAGNOSING PAINFUL AND NON-PAINFUL...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
December 20, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.